{"id":47810,"date":"2022-08-30T19:01:45","date_gmt":"2022-08-30T17:01:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/"},"modified":"2022-08-30T19:01:45","modified_gmt":"2022-08-30T17:01:45","slug":"geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/","title":{"rendered":"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody"},"content":{"rendered":"<div>\n<ul class=\"bwlistsquare\">\n<li>\n<b>The first publication confirms the neurotoxic role of HERV-K\/HML-2 ENV detected in the cerebrospinal fluid of sporadic ALS patients and the preclinical therapeutic effect of GeNeuro\u2019s anti-HERV-K ENV antibody in neutralizing HERV-K\/HML-2 ENV toxicity.<\/b>\n<\/li>\n<\/ul>\n<ul class=\"bwlistsquare\">\n<li>\n<b>The second publication provides a clinically based rationale for the therapeutic use of a specific neutralizing antibody addressing sporadic ALS neuropathology, by demonstrating the positive role of HERV-K ENV-specific but low-abundant natural autoantibodies on the duration of patients\u2019 survival.<\/b>\n<\/li>\n<\/ul>\n<ul class=\"bwlistsquare\">\n<li>\n<b>Sporadic ALS is a devastating disease affecting 10,000 new patients per year in the U.S. and Europe, with a very limited survival prognosis.<\/b>\n<\/li>\n<\/ul>\n<p>GENEVA&#8211;(BUSINESS WIRE)&#8211;GeNeuro (Euronext Paris: CH0308403085 &#8211; GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19 (post-COVID), announced today the joint publications in the leading scientific journal &#8220;Annals of Neurology&#8221; of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States. The two publications describe the novel pathogenic mechanism of HERV-K in sporadic ALS and confirm the rationale for the therapeutic relevance of GeNeuro&#8217;s antibody to neutralize this neurotoxic protein.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/5\/GeNeuro_-_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/21\/GeNeuro_-_logo.jpg\"><\/a><\/p>\n<p>\nAnnals of Neurology is an official journal of the American Neurological Association. The online publications and their hard copy version in the last issue of the journal (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1002%2Fana.26452&amp;esheet=52841539&amp;newsitemid=20220830005784&amp;lan=en-US&amp;anchor=HERV-K+envelope+in+spinal+fluid+of+Amyotrophic+Lateral+Sclerosis+is+toxic+-+Steiner+et+al%2C&amp;index=1&amp;md5=a0493de8836f21ca903b528eeb1a0767\" rel=\"nofollow noopener\" shape=\"rect\">HERV-K envelope in spinal fluid of Amyotrophic Lateral Sclerosis is toxic &#8211; Steiner et al,<\/a> &amp; <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Ffull%2F10.1002%2Fana.26466&amp;esheet=52841539&amp;newsitemid=20220830005784&amp;lan=en-US&amp;anchor=Antibody+response+to+HML-2+may+be+protective+in+Amyotrophic+Lateral+Sclerosis+-+Garcia-Montojo+et+al.+-+Annals+of+Neurology&amp;index=2&amp;md5=ce405cbdd8e5b91164327726bf9c9611\" rel=\"nofollow noopener\" shape=\"rect\">Antibody response to HML-2 may be protective in Amyotrophic Lateral Sclerosis &#8211; Garcia-Montojo et al. &#8211; Annals of Neurology<\/a>) present preclinical data showing that HERV-K\/HML-2 Envelope protein (HERV-K ENV) is present in the cerebrospinal fluid (CSF) of sporadic ALS patients, leads to neuronal cell injury and death, and targets a now identified cellular receptor. <b>The studies also show that the neurotoxic properties of the HERV-K ENV protein from ALS patients\u2019 CSF are neutralized by GeNeuro\u2019s anti-HERV-K ENV antibody and that, in patients with sporadic ALS, higher levels of autoantibodies targeting the HERV-K ENV protein are associated with a longer survival.<\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.geneuro.com%2Fen%2Fnews-press%2Fpress-releases-2&amp;esheet=52841539&amp;newsitemid=20220830005784&amp;lan=en-US&amp;anchor=Click+here+to+read+the+full+press+release&amp;index=3&amp;md5=a575521c15f1051f924df2b13c39a065\" rel=\"nofollow noopener\" shape=\"rect\">Click here to read the full press release<\/a>\n<\/p>\n<p>\n<b>About GeNeuro<\/b>\n<\/p>\n<p>\nGeNeuro\u2018s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.\n<\/p>\n<p>\nGeNeuro is based in Geneva, Switzerland and has R&amp;D facilities in Lyon, France. It owns rights to 17 patent families protecting its technology.\n<\/p>\n<p>\nFor more information, visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.geneuro.com%2F&amp;esheet=52841539&amp;newsitemid=20220830005784&amp;lan=en-US&amp;anchor=www.geneuro.com&amp;index=4&amp;md5=244d8a0eb7345a49bd1d8181fd56916a\" rel=\"nofollow noopener\" shape=\"rect\">www.geneuro.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>GeNeuro<\/b><br \/>Jes\u00fas Martin-Garcia<br \/>\n<br \/>Chairman and CEO<br \/>\n<br \/>+41 22 552 4800<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#108;&#x74;&#x6f;&#x3a;in&#118;&#101;&#x73;&#x74;&#x6f;&#x72;s&#64;&#103;&#101;&#x6e;&#x65;&#x75;&#x72;o&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;&#118;&#x65;&#115;&#x74;o&#x72;s&#x40;g&#101;&#x6e;&#101;&#x75;&#114;&#x6f;&#46;&#x63;o&#x6d;<\/a>\n<\/p>\n<p>\n<b>NewCap<\/b><br \/>Louis-Victor Delouvrier \/ Mathilde Bohin (investors)<br \/>\n<br \/>+33 1 44 71 98 52<br \/>\n<br \/>Arthur Rouill\u00e9 (media)<br \/>\n<br \/>+33 1 44 71 94 98<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#x3a;&#x67;e&#110;&#x65;&#x75;r&#111;&#x40;&#x6e;e&#119;&#x63;&#x61;p&#46;&#101;&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">&#103;e&#x6e;e&#x75;r&#x6f;&#64;&#x6e;&#101;&#x77;&#99;&#x61;&#112;&#x2e;&#101;u<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The first publication confirms the neurotoxic role of HERV-K\/HML-2 ENV detected in the cerebrospinal fluid of sporadic ALS patients and the preclinical therapeutic effect of GeNeuro\u2019s anti-HERV-K ENV antibody in neutralizing HERV-K\/HML-2 ENV toxicity. The second publication provides a clinically based rationale for the therapeutic use of a specific neutralizing antibody addressing sporadic ALS neuropathology, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47810","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The first publication confirms the neurotoxic role of HERV-K\/HML-2 ENV detected in the cerebrospinal fluid of sporadic ALS patients and the preclinical therapeutic effect of GeNeuro\u2019s anti-HERV-K ENV antibody in neutralizing HERV-K\/HML-2 ENV toxicity. The second publication provides a clinically based rationale for the therapeutic use of a specific neutralizing antibody addressing sporadic ALS neuropathology, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-30T17:01:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/21\/GeNeuro_-_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\\\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody\",\"datePublished\":\"2022-08-30T17:01:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/\"},\"wordCount\":483,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005784\\\/en\\\/519367\\\/21\\\/GeNeuro_-_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/\",\"name\":\"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\\\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005784\\\/en\\\/519367\\\/21\\\/GeNeuro_-_logo.jpg\",\"datePublished\":\"2022-08-30T17:01:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005784\\\/en\\\/519367\\\/21\\\/GeNeuro_-_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220830005784\\\/en\\\/519367\\\/21\\\/GeNeuro_-_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\\\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/","og_locale":"en_US","og_type":"article","og_title":"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody - Pharma Trend","og_description":"The first publication confirms the neurotoxic role of HERV-K\/HML-2 ENV detected in the cerebrospinal fluid of sporadic ALS patients and the preclinical therapeutic effect of GeNeuro\u2019s anti-HERV-K ENV antibody in neutralizing HERV-K\/HML-2 ENV toxicity. The second publication provides a clinically based rationale for the therapeutic use of a specific neutralizing antibody addressing sporadic ALS neuropathology, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-30T17:01:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/21\/GeNeuro_-_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody","datePublished":"2022-08-30T17:01:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/"},"wordCount":483,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/21\/GeNeuro_-_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/","url":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/","name":"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/21\/GeNeuro_-_logo.jpg","datePublished":"2022-08-30T17:01:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/21\/GeNeuro_-_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220830005784\/en\/519367\/21\/GeNeuro_-_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/geneuro-two-studies-on-als-published-in-annals-of-neurology-demonstrate-the-neurotoxic-role-of-human-endogenous-retrovirus-envelope-protein-herv-k-hml-2-env-and-the-rationale-for-targeted-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K\/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47810"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47810\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}